In line with this, inhibition of ATGL in mice using Atglistatin leads to improvement of insulin signalling and a reduction of diet-induced obesity and hepatosteatosis, likely due to a reduced release of adipose tissue-derived FAs in the circulation [178]. This evidence concerns the gene PNPLA2 and obesity disorder.